About Cidara Therapeutics
Cidara Therapeutics is a company based in San Diego (United States) founded in 2013 was acquired by Merck in November 2025. Cidara Therapeutics has raised $78.35 million across 8 funding rounds from investors including Merck, Fidelity Investments and NIH. The company has 38 employees as of December 31, 2024. Cidara Therapeutics offers products and services including Cloudbreak Platform. Cidara Therapeutics operates in a competitive market with competitors including BeiGene, Biological E, Vir Biotechnology, BioNTech and Freeline, among others.
- Headquarter San Diego, United States
- Employees 38 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cidara Therapeutics, Inc.
-
Annual Revenue
$1.27 M (USD)-94.52as on Dec 31, 2024
-
Net Profit
-$168.03 M (USD)-632.75as on Dec 31, 2024
-
EBITDA
-$90.99 M (USD)-237.71as on Dec 31, 2024
-
Total Equity Funding
$78.35 M (USD)
in 8 rounds
-
Latest Funding Round
$105 M (USD), Post-IPO
Nov 21, 2024
-
Investors
Merck
& 23 more
-
Employee Count
38
as on Dec 31, 2024
-
Acquired by
Merck
(Nov 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cidara Therapeutics
Cidara Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CDTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cidara Therapeutics
Cidara Therapeutics offers a comprehensive portfolio of products and services, including Cloudbreak Platform.
Platform creates drug-Fc conjugates for targeted disease treatment.
People of Cidara Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Cidara Therapeutics
Cidara Therapeutics has successfully raised a total of $78.35M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $105 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cidara Therapeutics
Cidara Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Fidelity Investments and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for Cidara Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cidara Therapeutics
Investment portfolio details for Cidara Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cidara Therapeutics
Detailed financials for Cidara Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cidara Therapeutics Comparisons
Peer comparison for Cidara Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cidara Therapeutics
Cidara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biological E, Vir Biotechnology, BioNTech and Freeline, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
Detailed competitors of Cidara Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cidara Therapeutics
Complete news archive for Cidara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cidara Therapeutics
Cidara Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Cidara Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Jeffrey Stein is the current CEO of Cidara Therapeutics.
Cidara Therapeutics is a funded company, having raised a total of $78.35M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cidara Therapeutics is 38.
Annual revenue of Cidara Therapeutics is $1.27M as on Dec 31, 2024.
Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.
Cidara Therapeutics offers Cloudbreak Platform.
Yes, Cidara Therapeutics is publicly traded on NASDAQ under the ticker symbol CDTX.
Cidara Therapeutics has 24 investors. Key investors include Merck, Fidelity Investments, NIH, RA Capital, and Frazier Healthcare Partners.
The ticker symbol of Cidara Therapeutics is CDTX on NASDAQ.